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A group of experts from EMBARC has generated a consensus definition of COPD and bronchiectasis
association based on the coexistence of radiological findings, bronchial obstruction, compatible
symptoms and exposure to smoke or toxic agents (ROSE criteria) https://bit.ly/3g3cdld
Cite this article as: Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction,
symptoms and exposure – a Delphi consensus definition of the association of COPD and
bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res 2021; 7: 00399-2021
[DOI: 10.1183/23120541.00399-2021].
Abstract
Introduction The coexistence of COPD and bronchiectasis seems to be common and associated with a
worse prognosis than for either disease individually. However, no definition of this association exists to
guide researchers and clinicians.
Methods We conducted a Delphi survey involving expert pulmonologists and radiologists from Europe,
Turkey and Israel in order to define the “COPD– [bronchiectasis] BE association”.
A panel of 16 experts from EMBARC selected 35 statements for the survey after reviewing scientific
literature. Invited participants, selected on the basis of expertise, geographical and sex distribution, were
asked to express agreement on the statements. Consensus was defined as a score of ⩾6 points (scale 0 to
9) in ⩾70% of answers across two scoring rounds.
Results 102 (72.3%) out of 141 invited experts participated in the first round. Their response rate in the
second round was 81%. The final consensus definition of “COPD–BE association” was: “The coexistence
of (1) specific radiological findings (abnormal bronchial dilatation, airways visible within 1 cm of pleura
and/or lack of tapering sign in ⩾1 pulmonary segment and in >1 lobe) with (2) an obstructive pattern on
spirometry ([forced expiratory volume in 1 s] FEV1/[forced vital capacity] FVC <0.7), (3) at least two
characteristic symptoms (cough, expectoration, dyspnoea, fatigue, frequent infections) and (4) current or
past exposure to smoke (⩾10 pack-years) or other toxic agents (biomass, etc.)”. These criteria form the
acronym “ROSE” (Radiology, Obstruction, Symptoms, Exposure).
Conclusions The Delphi process formulated a European consensus definition of “COPD–BE association”.
We hope this definition will have broad applicability across clinical practice and research in the future.
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Introduction
COPD and bronchiectasis are two of the most frequent chronic respiratory diseases, both representing
important causes of morbidity and mortality, as well as increasing burden for healthcare systems worldwide
[1, 2]. The definition of COPD is established by the Global Initiative for Obstructive Lung Disease (GOLD)
as “a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and
airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to
noxious particles or gases [3]”. Recently, an international study group involving experts from Europe
(EMBARC) and the USA has generated the first consensus definition of “clinically significant [bronchiectasis]
BE”, including specific clinical signs/symptoms and radiological findings [4].
Although these two entities individually have very different characteristics, the presence of bronchiectasis
and COPD in the same patient is quite frequent [5–7]. In fact, while usual clinical presentation of COPD is
mostly driven by dyspnoea and cough [3], in bronchiectasis chronic expectoration and recurrent respiratory
infections are the most frequent manifestations [8]. In the presence of compatible symptoms, the diagnostic
process is also different: in COPD it is based on a functional assessment (airflow limitation after
bronchodilatation), while in bronchiectasis it is based on a radiological evaluation (specific findings on
computed tomography (CT) scan) [3, 8]. Additionally, risk factors are different: the exposure to smoke or
other irritants is deemed necessary to confirm diagnosis of COPD, while in [bronchiectasis] BE they are
less clear and extremely heterogeneous depending on the patient’s age and comorbidities. Some specific
conditions, such as primary immunodeficiencies [9], gastro-oesophageal reflux [10] or lung tuberculous or
non-tuberculous mycobacteria infections [11], have been described as risk factors for developing
bronchiectasis. Additionally, severe chronic asthma [12] or COPD [13] are also considered risk factors for
developing secondary bronchiectasis. As a consequence, the epidemiology of COPD and bronchiectasis
may be very different depending on risk factors and other elements such as quality of access to healthcare
(spirometry and CT scan, among others) [11, 14, 15].
The epidemiology of the association between COPD and bronchiectasis is even less clear. In fact, the
reported prevalence of bronchiectasis in COPD patients varies considerably across series, from 4% to 75%
[5, 16–18]. Different factors can be invoked to understand such variability in prevalence rates: series differ
in inclusion criteria, severity of disease, definition of bronchiectasis and method used for radiological
diagnosis. Moreover, the presence of increased vessel size (such as in pulmonary hypertension), affecting
the broncho-arterial ratio, could be a cause of under-diagnosis when the broncho-arterial ratio is used as
diagnostic criteria on high-resolution computed tomography (HRCT) [19]. More commonly, however,
bronchiectasis may be overdiagnosed, as bronchial dilatation may be found in 10–30% of CT scans of
healthy and asymptomatic subjects over 40 years of age [20, 21]. Also, the presence of hypoxic
vasoconstriction, frequent in chronic pulmonary diseases, could contribute to bronchiectasis overdiagnosis [17].
This variability in broncho-arterial ratio and its interpretation may influence the diagnosis of bronchiectasis and,
even more frequently, in COPD patients [9].
Across the limited number of bronchiectasis studies where the prevalence of COPD has been reported, it
has ranged between 8.8% and 32% [13, 21–24]. In these studies, in the absence of an established
definition of COPD–BE association, the diagnosis of COPD was based on a functional obstructive pattern
and, in some cases, smoking history.
Regardless of the primary diagnosis, the coexistence of COPD and bronchiectasis is usually associated
with greater symptom burden, greater frequency and severity of exacerbations, more severe airways
obstruction and increased mortality risk compared with any of the two diseases alone [18, 25, 26]. Owing
to all these reasons, an international group of experts has worked towards achieving a consensus definition
of the association of COPD and bronchiectasis independently of the primary diagnosis. Such a definition
will allow, first, a standardised epidemiological data collection and, second, to assess the health-economic
burden of this association. Moreover, a consensus definition could be a critical tool to better select patients
for future clinical trials.
Methods
Design of the study
This was a Delphi survey with the objective of developing an international consensus definition of the
COPD–BE association.
Delphi is a consensus method developed to measure levels of agreement between experts on a subject
where scientific evidence is lacking, limited or contradictory [27]. The Delphi method is based on four
characteristics: 1) anonymity: guaranteed by the centralisation of questionnaire answers by a single
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moderator; 2) iteration: meaning that the same questions are reiterated in successive rounds until reaching
stability in answers; 3) controlled feedback: participants are provided with feedback of previous rounds
before proceeding with the following ones – the moderator can usually decide how much information will
be provided after each round and the means by which this is delivered; and 4) statistical “group response”,
usually measured with central tendency, dispersion and frequency distributions [28–30].
Additionally, this method allows the collection of numerous expert opinions without the need of
face-to-face meetings. Methods were repeatedly discussed within the panel in order to enhance validity and
avoid methodological biases.
In our Delphi, a panel of experts selected the statements to be graded by survey respondents, in order to
describe the association between COPD and bronchiectasis. The items receiving the highest level of
concordance after two rounds were selected as the criteria forming the final definition.
Participants in the survey
The Delphi survey was designed by a panel of 16 experts in COPD and bronchiectasis from the EMBARC
Airways Working Group, including a small group of radiologists with specialised interest in thoracic
imaging.
The panel selected participants trying to ensure a diverse distribution by sex, geography and expertise (for
COPD, bronchiectasis or both and thoracic radiology) in order to obtain a solid representation of opinions
while respecting Delphi method recommendations [27–30]. We planned a target of 100 responses;
therefore, assuming ∼20% will be non-responders, a total of 125 invitations were sent to accredited experts
in the fields of COPD, bronchiectasis and thoracic radiology from European countries, Turkey and Israel,
selected based on published literature in the field. A pool of radiologists (20% of total invitations) was
included due to the important role played by radiology in the diagnosis of bronchiectasis. Moreover, the 16
members of the panel were also invited to complete the survey.
Development of the survey
Initially, the panel performed a scoping review of the literature regarding the association of COPD and
bronchiectasis and discussed the findings, identifying crucial issues and common points in prior studies
related to the association. After setting the aim of the definition, each panellist proposed statements for
internal discussion. From the original list, the panel formulated a short list of 35 statements split into five
categories: clinical, functional, microbiological, radiological and pathophysiological features (table 1).
Elaboration of consensus definition
Participants were invited to grade the selected statements from 0 (completely disagree) to 9 (fully agree).
Radiologists were asked to only complete the radiology section of the survey, while clinicians completed
all sections.
After the first round, the panel defined consensus as the scoring of at least 6 points (positive consensus) or
fewer than 4 points (negative consensus) in ⩾70% of the responders, according to Delphi methodology [21].
Furthermore, after the analysis of results from the first round, the second round was designed where some
questions were reiterated, some were reformulated to improve clarity and some new questions were added to
enhance the quality of the definition.
Finally, the panel formulated the consensus definition with the criteria that reached the higher level of
consensus at the end of the second round.
Results
First round
The first round of the survey was open from January 30 to April 24, 2019, with 102 responders (response
rate 72%, females 40%). Among them, 18% were radiologists, 38% were COPD experts, 38%
bronchiectasis experts and 7% were pulmonologists working on both diseases. Responders represented 30
countries: Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, France, Germany, Greece, Ireland,
Israel, Italy, Latvia, Lithuania, Macedonia, Malta, Moldova, the Netherlands, Norway, Poland, Portugal,
Romania, Russia, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey and the UK.
Despite the initial attempt to have a homogeneous distribution of survey participants from different
European regions, we finally had seven additional responders from countries with more centres dedicated
to COPD and bronchiectasis in order to ensure the target number of 100 participants (figure 1).
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After the analysis of results from the first round, five statements reached positive consensus and passed to
the second round: “airways visible within 1 cm of the pleura”; “BE in at least one pulmonary segment in
more than one lobe”; “lack of tapering sign”; “post-bronchodilator [forced expiratory volume in 1 s] FEV1/
[forced vital capacity] FVC <0.7”; “current or past smoking habit (⩾10 pack-years) or history of other
exposure to toxic inhalants (biomass, industrial, etc)” (figure 2).
Negative consensus was reached only by two statements: 1) “a mixed ventilatory pattern excludes the
diagnosis”; and 2) “history of positive bronchodilation test excludes the association”.
In the radiology section, three very similar assertions about distribution of bronchiectasis obtained a high
score, although only one reached the consensus threshold. Therefore, the panel decided to include all of
them in the second round in order to reiterate the information and achieve a better agreement.
All the other statements obtained an intermediate result and therefore were excluded from the second
round. No microbiological, clinical or pathophysiological items passed the first round, except for history of
TABLE 1 Final list of statements included in the Delphi survey
Clinical items required to define the association of COPD and bronchiectasis
1. Age >35 years
2. Current or past smoking habit (⩾10 pack-years) or other toxic exposure (biomass, industrial, etc.)
3. Presence of at least 15 mL of expectorated sputum most of the days
4. Presence of purulent sputum most of the days
5. Presence of haemoptysis
6. Presence of chronic cough and expectoration for at least 3 consecutive months in the last 2 years
7. Presence of dyspnoea (mMRC ⩾1) in the last 2 years
8. History of at least one exacerbation in the previous year
9. History of frequent infectious exacerbations (⩾2)
10. History of at least one severe exacerbation in the last year (hospitalisation or intravenous antibiotic
therapy)
Radiological items required to define the association of COPD and bronchiectasis
11. Lack of airway tapering sign
12. Airways visible within 1 cm of the pleural surface
13. BE (bronchial dilatation) in at least one pulmonary segment in one lobe
14. BE (bronchial dilatation) in more than one pulmonary segment in one lobe
15. BE (bronchial dilatation) in one or more pulmonary segments in more than one lobe
16. Presence of extensive emphysema
17. Extensive bronchial wall thickening
18. Presence of diffuse mucus plugging
19. Presence of air trapping
Functional items required to define the association of COPD and bronchiectasis
20. Post-bronchodilator FEV1/FVC <0.7
21. Post-bronchodilator FEV1/FVC <LLN
22. A positive BD test excludes the diagnosis of COPD–BE association
23. A mixed (restrictive/obstructive) pattern excludes the diagnosis of COPD–BE association
24. A history of positive BD test excludes the diagnosis of COPD–BE overlap
25. A documented history of asthma excludes the diagnosis of COPD–BE overlap
Microbiological items required to define the association of COPD and bronchiectasis
26. At least one isolation of PPM in sputum in the last year in steady state
27. >1 isolation of PPM in sputum in the last year in steady state
28. History of chronic bronchial infection by any PPM in steady state
29. Isolation of Pseudomonas aeruginosa in sputum
30. No isolation of PPM
Pathophysiological items required to define the association of COPD and bronchiectasis
31. Blood leukocytosis in stable clinical conditions
32. High blood level of C-reactive protein in stable clinical conditions
33. High blood level of fibrinogen in stable clinical conditions
34. High neutrophil count in sputum in stable clinical conditions
35. High eosinophil count in serum in stable clinical conditions
Participants were asked to grade each item, according to their level of agreement on the necessity for the
statement to be part of the COPD–BE association definition. mMRC: modified Medical Research Council;
BE: bronchiectasis; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal;
BD: bronchodilation; COPD: chronic obstructive pulmonary disease; PPM: potential pathogenic microorganisms.
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exposures. To confirm the exclusion of these potentially relevant categories from the definition, the panel
introduced new specific questions regarding microbiological and clinical items and gave responders the









FIGURE 1 Geographical distribution of participants to the survey. Countries have been grouped according to
EuroVoc criteria [24]. #: only European countries are represented in the map; responders from Turkey and Israel





















































































































































































































































































































































































































































































FIGURE 2 Results from the first round. Statements were graded from 1 (completely disagree) to 9 (completely agree). Consensus was defined as at
least 70% of answers scored 6 or higher (dashed line). PPM: potential pathogenic microorganisms; BD: bronchodilation test; CRP: C-reactive
protein; mMRC: modified Medical Research Council; BE: bronchiectasis; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LLN: lower
limit of normal.
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Second round
The second round ran between the end of June and the end of July 2019 and 16 statements were included:
five on clinical features, five on radiological features, one on functional features and five on
microbiological features (table 3). All responders from the first round were contacted and invited to
TABLE 2 Second round: additional questions#
Clinical items required to define the association of COPD and bronchiectasis
In addition to the criteria already selected, should any clinical aspect be included in order to ensure only
symptomatic patients are considered? (YES/NO)
If answered yes to this question, then chose one of the following:
a) Should the definition of COPD–BE include at least ONE of the following signs and symptoms: cough,
expectoration, dyspnoea, fatigue, frequent infections (⩾2)?
b) Should the definition of COPD–BE include at least TWO of the following signs and symptoms: cough,
expectoration, dyspnoea, fatigue, frequent infections (⩾2)?
c) OPEN QUESTION: is there a sign or symptom you consider essential to define COPD–BE association?
Microbiological items required to define the association of COPD and bronchiectasis
In addition to the criteria already selected, should any microbiological aspect be included? (YES/NO)
If answered yes to this question, then chose one of the following:
a) To define COPD–BE association the following criterion is required: at least one isolation of PPM in
sputum in the last year in steady state
b) To define COPD–BE association the following criterion is required: >1 isolation of PPM in sputum in the
last year
c) To define COPD–BE association the following criterion is required: history of chronic bronchial infection
(two or more isolates of the same organism at least 3 months apart in 1 year, see ERS guidelines) by any
PPM
BE: bronchiectasis; PPM: potentially pathogenic microorganisms. #: in case of an affirmative answer to the
primary question (in bold), secondary questions were performed.
TABLE 3 Second round results
Confirmation of statements % of answers Mean score
Smoking habit and exposures# 85 7.7
Post-bronchodilator FEV1/FVC <0.7
# 93 8.1
Lack of tapering sign 83 7.3
Airways <1 cm of pleura¶ 87 7.1
BE ⩾1 pulmonary segment in one lobe¶ 64 5.8
BE >1 pulmonary segment in one lobe¶ 70 6.2
BE ⩾1 pulmonary segment in more than one lobe¶ 73 6.6
Clinical and microbiological aspects#
2.1 Should any clinical aspect be included? YES 76%
Between “yes” responders (n=51) % of answers Mean score
At least ONE symptom 65 5.9
At least TWO symptoms 84 7.5
2.2 Should any microbiological aspect be included? YES 39%
Between “yes” responders (n=26): % of answers Mean score
At least one isolation of PPM stability 65 6.1
More than one isolation of PPM in sputum in the last year 54 5.7
Chronic bronchial infection by any PPM 65 6.4
Pseudomonas ever isolated in sputum 46 5.2
In the second column, the percentage of answers graded 6 points or more. In the third column, the mean score
received. FEV1: forced expiratory volume in the 1 s; FVC: forced vital capacity; BE: bronchiectasis; PPM: potential
pathogenic microorganisms. Where not specified, expressed percentages refer to the number of responders:
#: 67 responders (only pulmonologists); ¶: 83 responders (pulmonologists+radiologists).
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participate once again. The response rate at the second round was 81% (83 responders). As for the first
round, radiologists (17 out of 83) were asked to answer exclusively the radiology section, while respiratory
specialists (67 out of 83) completed the entire survey.
As expected, all the questions that reached consensus at the first round were confirmed, with a higher level
of concordance between responders.
With regard to clinical features, 51 participants (76% of the pulmonologists) agreed on the need to include
at least a clinical criterion in the final definition of COPD–BE association. Among them, 84% (43 out of
51) chose to include the presence of at least two symptoms between those listed (cough, expectoration,
dyspnoea, fatigue, frequent infections) in the definition. 29 “yes” responders (56%) also answered the open
question: all the proposed symptoms were coherent with those listed in the previous list (table 4).
Conversely, the exclusion of microbiological characteristics from the definition was widely confirmed by
61% of pulmonologists (41 out of 67) (table 3). Owing to the high consensus reached, the panel decided
not to perform a third round.
According to final responses of the second round, the panel formulated the consensus definition expressed
in table 5.
These criteria form the “ROSE” acronym (Radiology, Obstruction, Symptoms, Exposure, figure 3).
Discussion
The need to phenotype chronic respiratory disease patients has been frequently raised, mostly in order to
adopt personalised treatments and improve outcomes [31–32]. This is particularly challenging when
different pathological conditions coexist, as in the case of COPD–BE association.
The presence of COPD and bronchiectasis in a single patient has frequently been reported [5–7, 17].
Furthermore, numerous studies have shown that this association has a more severe clinical presentation and
worse prognosis than each individual disease [17, 18, 33–38]. However, there is no consensus on how this
association should be defined. Indeed, many experts have provided different interpretations of this
association [5, 39]. Some authors such as HURST et al. [5, 40] have discussed the existence of a “COPD–
BE overlap syndrome”, which might suggest the existence of a unique and distinctive clinical entity with
different clinical, radiological or biological characteristics compared to the two diseases alone [5].
However, after internal discussion, the panel decided not to adopt an overlap definition for coexisting
TABLE 4 Answers to open question “is there a sign or symptom you consider essential to define BE–COPD association”
Open question Answers n Detailed answers
Total responders 29
Expectoration 18 Bronchorrhea, chronic sputum, chronic phlegm, phlegm production, purulent sputum
Cough 4
Recurrent infections 11 Frequent infections, frequent lower respiratory infections, more than one exacerbation per year, infections
including pneumonia
Answers were grouped into three clusters according to similarity of answers. Detailed answers are listed in third column.
TABLE 5 Final consensus definition
The association of COPD and bronchiectasis is defined as the presence of at least four elements
1. RADIOLOGICAL: Abnormal bronchial dilatation in one or more pulmonary segment in more than one lobe
and specific radiological findings (airways visible within 1 cm of pleura and/or lack of tapering sign) plus
2. OBSTRUCTION: a functional obstructive pattern (post-bronchodilator FEV1/FVC <0.7), plus
3. SYMPTOMS: two or more of the following symptoms: cough, expectoration, dyspnoea, fatigue, frequent
lower airway infections (⩾2/year) plus
4. EXPOSURE: current or past smoking habit (⩾10 pack-years) or other toxic exposure (biomass, industrial,
etc.)
FEV1: forced expiratory volume in the 1 s; FVC: forced vital capacity.
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COPD and bronchiectasis, considering the lack of supporting evidence. At the present time, the
understanding of biological and pathogenetic interaction between these two conditions is still poor and, in
our opinion, definitely not enough to justify the description of a new clinical entity. Alternative concepts
have been proposed, including the idea of using clinical criteria to determine the “dominant” condition for
therapy, either bronchiectasis as a phenotype of COPD or chronic airflow obstruction in a patient with
bronchiectasis. This approach is difficult to standardise across different centres as objective methods of
defining dominant conditions have not yet been defined. Instead, the panel decided to consider the
presence of COPD and bronchiectasis as an association of two different defined diseases, with complex
and not fully understood mutual interactions.
The pathophysiology of this association is still uncertain. Indeed, it is not clear whether the presence of
bronchiectasis could increase susceptibility to tobacco smoking, leading to more rapidly progressive
functional and clinical decline and, therefore, the development of COPD; or conversely, whether the
development of bronchiectasis could be part of the natural history of COPD [5]. Recently, a long-term
observational study by Martinez-Garcia et al. [26] identified the presence of chronic purulent sputum
production, potentially pathogenic microorganisms (PPM) in sputum and frequency of hospitalisations due
to COPD exacerbations as independent, preventable and treatable risk factors for bronchiectasis emergence
or progression in COPD patients. More data are needed to unravel this issue, and we believe that a
definition is crucial in order to optimise the development of evidence in the field, to guide future trials and
to produce useful clinical recommendations.
To satisfy these needs, the definition should be simple, clear and helpful, and ideally useful for clinical
settings as well as for research. Owing to the lack of agreement in the current literature, we decided to
approach this problem by assessing the opinion of professionals with different backgrounds, through a
Delphi survey and, finally, to produce a consensus definition. To our knowledge, this is the first attempt to
systematically address this need.
An optimal geographical distribution of responders was sought, but unfortunately it could be only partially
achieved. In fact, Eastern Europe, the most populated European region, only accounted for 16% of
respondents, while most came from the UK, Spain and other central and southern European countries. It
possibly reflects the different levels of experience and scientific interest in bronchiectasis across European
countries, also suggested by preliminary data from the European bronchiectasis registry (EMBARC) [41].
Of course, this distribution is a potential source of bias, due to the variability between different
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FIGURE 3 The “ROSE” criteria: Radiology, Obstruction,
Symptoms, Exposure, defining the association of COPD and
bronchiectasis. FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity; p/y: pack-years.
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The final consensus definition of the association of COPD and bronchiectasis corresponds to the acronym
ROSE for the four components: Radiology, Obstruction, Symptoms and Exposure. Responses obtained
from participants reflect the importance of radiology for the diagnosis of bronchiectasis in COPD patients.
In fact, highest consensus was obtained by statements derived from Naidich criteria [42]; however,
statements regarding the extent and distribution of bronchiectasis had to be reiterated on the second round
for confirmation, when finally a clear agreement was achieved: abnormal bronchial dilatation needs to be
extensive (“one or more pulmonary segment in more than one lobe”) to define the pathological association
of COPD and bronchiectasis.
Other radiological criteria such as the presence of bronchial wall thickening received a borderline score
(68%). Both radiologists and pulmonologists in the panel agreed on excluding it from the second round,
being a nonspecific marker of inflammation present in different respiratory conditions. Similarly, the
broncho-arterial ratio was not included in the statements of our survey, due to its lack of specificity for the
association COPD–BE. As stated before, the broncho-arterial ratio in patients with both COPD and
bronchiectasis can be influenced by several factors, such as pulmonary hypoxic vasoconstriction, advanced
age and increased vessel size due to pulmonary hypertension, among others [19, 43].
According to GOLD, bronchial obstruction is needed to define the presence of COPD [3], therefore
representing an essential feature in any comorbid association. Indeed, the presence of airflow obstruction is
a necessary but not sufficient condition to establish a COPD diagnosis. Conversely, in pure bronchiectasis
a wide variability of functional patterns has been described [23]. Persistent airflow obstruction is frequent
in symptomatic bronchiectasis patients without smoking history or other risk factors for COPD. This could
be associated with misdiagnosed COPD in a variable proportion of bronchiectasis patients, possibly
leading to a delay in bronchiectasis diagnosis if HRCT is not performed [23, 44–46].
Regarding symptoms, no clinical criteria reached the expected level of consensus in the first round.
Nevertheless, considering the importance of clinical manifestations in both COPD and bronchiectasis, the
panellists considered the possibility that the first-round statements might have lacked clarity and
reformulated them in the second round, getting the approval of most responders. Indeed, the included
symptoms are unspecific and common to a variety of chronic respiratory conditions, but still necessary to
define this clinical association. The panel used the following threshold to define “frequent lower airway”:
at least two exacerbations/year or one hospitalisation/year. This decision was taken in consideration of the
available literature on frequent exacerbator phenotypes in both COPD and bronchiectasis [47–51]. The
inclusion of smoking or toxic exposures received a high level of consensus since the first round. In fact,
cigarette smoking represents the main risk factor for COPD in high-income countries [3]. The threshold of
10 pack-years was chosen since it is generally accepted as the minimum significant exposure to develop
COPD [3]. Biomass exposure was also considered for the definition as it can be a relevant cause of COPD in
low-income countries [52], and COPD development can be expected after 10–15 years of exposure [53, 54].
Apart from the criteria that were included in the ROSE definition, we explored other aspects of COPD–BE
association that did not reach consensus. For instance, none of the statements proposed in the
pathophysiological section achieved consensus, highlighting the fact that we currently lack any relevant
biological marker of this association. Among the excluded variables, age >35 years (68%) obtained a
borderline score. In concordance with the responders, although the association of COPD–BE is a disease
of the adult population, the panellists also felt that it was impossible to define an age threshold for the
onset of both COPD and bronchiectasis. This decision finds confirmation in a prevalence study from
China, where an increasing number of individuals with COPD were >20 years old [55].
Despite the importance of respiratory infections, respondents did not consider microbiological criteria
essential to define the COPD–BE association. Respiratory infections are one of the most frequent clinical
manifestations and alarm signs to suspect bronchiectasis, while in COPD they are a potential marker of
disease severity and/or can suggest the need for a therapeutic step-up. Nevertheless, respiratory infections
do not represent an exclusive criterion to define any respiratory condition, being nonspecific complications
of most airway diseases.
However, in view of ongoing research on clinical and biological phenotypes of the COPD–BE association,
the perceived importance of biological or microbiological markers could change in the future. For example,
isolation of Pseudomonas aeruginosa or Haemophilus influenzae has already been identified as a risk
factor for bronchiectasis in patients with COPD [25, 56, 57]. Moreover, both bacterial and fungal
infections of the airways have been described as being more prevalent in patients with both COPD and
bronchiectasis [58–58], though no specific phenotypes have been identified yet.
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In conclusion, the EMBARC Working Group on Airways Diseases agreed that the definition of COPD–BE
association requires the coexistence of specific radiological signs and a functional obstructive pattern
associated with the presence of at least two characteristic symptoms and current or past exposure to
smoke or other toxic agents, which can be summarised in the acronym ROSE.
Future validation of this definition in a clinical setting is necessary, together with pheno- and/or
endotyping studies to assess the biological and functional patterns of patients with COPD and
bronchiectasis. In this group of patients, the identification of treatable traits will be important for
management, appropriate enrolment in clinical trials and for new drug registration purposes.
Hopefully, the present consensus definition of COPD–BE can be the first step in guiding risk stratification
and clinical management of patients with this association after an appropriate validation in international
cohorts of patients with COPD and/or bronchiectasis.
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